Aspen Neuroscience, Inc.: Frazier Life Sciences X, L.P. discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Frazier Life Sciences X, L.P. disclosed a stake exceeding 5% in Aspen Neuroscience, Inc. via a Schedule 13G filing with the SEC (accession 0001231919-26-001553). The filing signals the venture firm's sizable position in the privately held biotech, which develops cell therapies for neurodegenerative disease. The exact share count and percentage were not specified in the filing summary. Investors should watch for further 13G amendments and any eventual IPO or financing round that could clarify the position's value.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Aspen Neuroscience, Inc., Frazier Life Sciences X, L.P.